Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells 25,000 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 25,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now directly owns 2,158,985 shares in the company, valued at $91,713,682.80. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Ultragenyx Pharmaceutical Trading Down 0.4 %

NASDAQ RARE traded down $0.16 on Tuesday, hitting $41.10. 1,385,598 shares of the company’s stock traded hands, compared to its average volume of 779,217. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm’s 50-day moving average price is $42.86 and its two-hundred day moving average price is $49.03. The firm has a market capitalization of $3.80 billion, a PE ratio of -6.48 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on RARE shares. JPMorgan Chase & Co. cut their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Wedbush reissued a “neutral” rating and set a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $93.50.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 493 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $35,000. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $42,000. True Wealth Design LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $43,000. Finally, Van ECK Associates Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 273 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.